Skip to content

ABBVIE

Active
Public limited company·Groothandel in farmaceutische en medische artikelen· 14 yrs active
Avenue Einstein 14 ·1300 Wavre, Belgium
KBO/BCE: BE 0845.096.860
Watch Print / PDF
Age14 yrs
Board5
Real estate2 parcels · 1.6 ha

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of ABBVIE is 0.8% (low). The company has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.

Based on State Gazette and CBE data.

Filing behaviour

From the deposit records, complete market-wide
Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-06-2026, 53 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.
The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
How we compute the deadline
The year end is derived from 10 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 08-06-2026 53 d early 2026-00155854
31-12-2024 31-07-2025 17-06-2025 44 d early 2025-00153639
31-12-2023 31-07-2024 07-06-2024 54 d early 2024-00117459
31-12-2022 31-07-2023 12-06-2023 49 d early 2023-00124464
31-12-2021 31-07-2022 09-06-2022 52 d early 2022-20052794
31-12-2020 31-07-2021 09-06-2021 52 d early 2021-18200254
31-12-2019 31-07-2020 30-06-2020 31 d early 2020-26700015
31-12-2018 31-07-2019 22-07-2019 9 d early 2019-35200091
31-12-2017 31-07-2018 20-06-2018 41 d early 2018-20000300
31-12-2016 31-07-2017 22-06-2017 39 d early 2017-21700305

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals
Established
Founded in 2012, 14 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.8% Low
0%0,5%1,5%4%10%≥25%
Multiple establishment units +Lower-risk legal form −Higher-failure-rate sector +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

Annual accounts & ratios

Source: NBB
Financials being processed
NBB has 10 filing(s) on record for this company, latest fiscal year 2025 (volledig). The annual accounts are being processed.
Filings on record
Fiscal year Type Filed Reference
31-12-2025 volledig 08-06-2026 2026-00155854
31-12-2024 volledig 17-06-2025 2025-00153639
31-12-2023 volledig 07-06-2024 2024-00117459
31-12-2022 volledig 12-06-2023 2023-00124464
31-12-2021 volledig 09-06-2022 2022-20052794
31-12-2020 volledig 09-06-2021 2021-18200254
31-12-2019 volledig 30-06-2020 2020-26700015
31-12-2018 volledig 22-07-2019 2019-35200091
31-12-2017 volledig 20-06-2018 2018-20000300
31-12-2016 volledig 22-06-2017 2017-21700305

Directors

Directors & mandates

14 directors
Current directors & mandates
  • Rolfe van de Spreng
    Director
    State Gazette act 26001766 (06-01-2026)
    Current
    01-12-2025 → present
  • Arnaud Jean Jacques Coint-Bavarot
    Director
    State Gazette act 22061007 (19-05-2022)
    Current
    01-05-2022 → present
  • Meike Elisabeth Celine Colette Kerstens
    Director
    State Gazette act 22061007 (19-05-2022)
    Current
    01-05-2022 → present
  • Renaud Decroix
    Director
    State Gazette act 24092666 (19-06-2024)
    Current
    01-08-2020 → present
    3 events
    • 19-06-2024 Mandate renewed· Director
    • 01-08-2020 Appointed· Director
    • 01-08-2020 Appointed· Managing director
  • Jean Antoine De Los Frailes
    Director
    State Gazette act 23078580 (16-06-2023)
    Current
    08-12-2017 → present
    3 events
    • 01-12-2025 Resigned· Director
    • 16-06-2023 Mandate renewed· Director
    • 08-12-2017 Appointed· Director
Historic, not recently confirmed (1)
These mandates remain open in the register but have not been confirmed by a new act in over six years. They do not count as active directors.
  • Robert Andrew Michael
    Director
    State Gazette act 19065393 (14-05-2019)
    Not recently confirmed
    last confirmed in an act from 2019
Former directors (8)
  • Meike Kerstens
    Director
    State Gazette act 24062759 (17-04-2024)
    Former
    - → 12-04-2024
  • Robert Michael
    Director
    State Gazette act 22061007 (19-05-2022)
    Former
    - → 01-05-2022
  • Thibault Massart
    Director
    State Gazette act 16124906 (08-09-2016)
    Former
    11-05-2016 → 31-07-2020
    4 events
    • 31-07-2020 Resigned· Director
    • 31-07-2020 Resigned· Managing director
    • 11-05-2016 Appointed· Director
    • 11-05-2016 Appointed· Managing director
  • William Chase
    Director
    State Gazette act 19065393 (14-05-2019)
    Former
    - → 29-03-2019
  • Jean Louis Gantmacher
    Director
    State Gazette act 15073651 (22-05-2015)
    Former
    11-05-2015 → 31-08-2017
    2 events
    • 31-08-2017 Resigned· Director
    • 11-05-2015 Appointed· Director
  • Jaroslaw Oleszczuk
    Managing director
    State Gazette act 15023938 (12-02-2015)
    Former
    01-12-2014 → 11-05-2016
    4 events
    • 11-05-2016 Resigned· Director
    • 11-05-2016 Resigned· Managing director
    • 01-12-2014 Appointed· Managing director
    • 01-12-2014 Appointed· Director
  • Valérie Buyse
    Director
    State Gazette act 15073651 (22-05-2015)
    Former
    - → 17-04-2015
  • Jérôme Bouyer
    Director
    State Gazette act 15023938 (12-02-2015)
    Former
    - → 01-12-2014
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.

Statutory auditor

1 auditor
Statutory auditor IRE/IBR number Tenure
EY Réviseurs d'Entreprises SRLCurrent
Statutory auditor · represented by Thomas Meurice
 - 03-09-2025 → present
Appointed statutory auditor from the Belgian State Gazette. The IRE/IBR number refers to the register of the Institute of Registered Auditors.

Insolvency mandates

No insolvency mandates (liquidators, administrators) on record for this company.

Legal Structure

NACE primary Groothandel in farmaceutische en medische artikelen(46460)
Legal form Public limited company(014)
Incorporation05-04-2012
StatusActive
Postal code1300

Structure & network

Locations & real estate

Establishment units

2 locations
Abbvie
Avenue Einstein 14, 1300 WavreVervaardiging van salicylzuur en o-acetylsalicylzuur
since 20122.209.035.141
Abbvie
de Meeûssquare 37, 1000 BrusselVervaardiging van salicylzuur en o-acetylsalicylzuur
since 20152.239.363.675
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels2
Ground area1.6 ha
Buildings2
Building footprint1,727 m²
Volume (LiDAR)31,579 m³
Tallest building32.6 m · ±8 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Wallonia 1 (50%) Brussels 1 (50%)
Parcel (capakey) Region Area Buildings Height / fl.
25112N0041/00B000 Wallonia 1.5 ha 1 · 832 m² 21.3 m · 6 fl.
21805E0463/00W002 Brussels 1,034 m² 1 · 895 m² 32.6 m · 8 fl.
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgisch Staatsblad · acts

28 acts
Capital history · 4
19-05-2022
v3.2
20-01-2022
v3.2
14-09-2016
v3.2
25-08-2014
v3.2
All acts · 28 updated 3 months ago
2026
07-05-2026 Officer resignation · Officer appointment · Mandate compensation · Mandate term Open-capture extraction
  • Filing: 2026-04-23 · Abbvie
  • Publication: 2026-05-07 · Abbvie
  • Officer resignation: date: 2026-04-01, role: administrateur · Rolfe van de Spreng
  • Officer appointment: date: 2026-04-01, role: administrateur · Erica Silbiger
  • Mandate compensation: amount: 0, currency: EUR · Erica Silbiger
  • Mandate term: end_condition: assemblée générale ordinaire des actionnaires qui se tiendra en 2028 · Erica Silbiger
  • Representation rule: rule: le conseil d'administration ou par deux administrateurs agissant conjointement · Abbvie
  • Representation rule: rule: la personne à qui cette gestion journalière a été déléguée · Abbvie
  • Power of attorney: date: 2026-04-01, scope: signature des formulaires I, II et de tout autre document nécessaire en vue du dépôt et de la publication · Nathalie Boonen
  • Power of attorney: date: 2026-04-01, scope: signature des formulaires I, II et de tout autre document nécessaire en vue du dépôt et de la publication · Jean-François Mouchet
  • Act object: Démission et nomination d'un administrateur
Summary: Officer resignation · Officer appointment · Mandate compensation · Mandate term
06-01-2026 1 director appointed, 1 resigning Director changes
  • Rolfe van de Spreng, Bestuurder
  • Jean-Antoine de Los Frailes, Bestuurder
Summary: v3.2
2025
03-09-2025 Thomas Meurice reappointed as statutory auditor Director changes
  • Thomas Meurice, Commissaris
Summary: v3.2
2024
23-08-2024 General meeting · Board meeting · Officer appointment · Officer reappointment Open-capture extraction
  • Publication: 23/08/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
  • Filing: 19/06/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
  • General meeting: 13/03/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
  • Board meeting: 15/05/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
  • Officer appointment: role: bestuurder, start_date: 2024-03-13 · Bayer N.V.
  • Officer reappointment: role: bestuurder, start_date: 2024-03-13 · AbbVie N.V.
  • Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Eli Lilly Benelux N.V.
  • Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Pfizer N.V.
  • Officer reappointment: role: bestuurder, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals N.V.
  • Officer resignation: date: 2024-03-13, role: bestuurder · Takeda Belgium N.V.
  • Officer appointment: role: ondervoorzitter van de Raad van Bestuur, start_date: 2024-05-15 · An Van Gerven
  • Permanent representative · Werner De Prins
  • Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
  • Permanent representative: start_date: 14/06/2024 · Niels Hessmann
  • Statute amendment · Algemene Vereniging van de Geneesmiddelenindustrie
Summary: General meeting · Board meeting · Officer appointment · Officer reappointment
23-08-2024 Act object · General meeting · Officer appointment · Officer reappointment Open-capture extraction
  • Act object: Nomination administrateurs - nomination vice-présidente Conseil d'administration - modifications aux statuts - nouveaux représentants permanents des administrateurs · Association Générale de l'Industrie du Médicament
  • Publication: 23/08/2024 · Association Générale de l'Industrie du Médicament
  • Filing: 19/06/2024 · Association Générale de l'Industrie du Médicament
  • General meeting: 13/03/2024 · Association Générale de l'Industrie du Médicament
  • Officer appointment: role: administrateur, start_date: 2024-03-13 · Bayer S.A.
  • Officer reappointment: role: administrateur, start_date: 2024-03-13 · AbbVie S.A.
  • Officer reappointment: role: administrateur, start_date: 2024-03-13 · Eli Lilly Benelux S.A.
  • Officer reappointment: role: administrateur, start_date: 2024-03-13 · Pfizer S.A.
  • Officer reappointment: role: administrateur, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals S.A.
  • Officer resignation: date: 2024-03-13, role: administrateur · Takeda Belgium S.A.
  • Statute amendment: Modifications aux statuts approuvées par l'AGE du 13 mars 2024 (articles 2, 5, 9, 12, 16, 28 et dispositions transitoires) · Association Générale de l'Industrie du Médicament
  • Board meeting: 15/05/2024 · Association Générale de l'Industrie du Médicament
  • Officer appointment: role: Vice-Présidente, start_date: 2024-05-15 · An Van Gerven
  • Permanent representative · Werner De Prins
  • Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
  • Permanent representative: start_date: 14/06/2024 · Niels Hessmann
Summary: Act object · General meeting · Officer appointment · Officer reappointment
19-06-2024 Renaud Decroix reappointed as director Director changes
  • Renaud Decroix, Bestuurder
Summary: v3.2
17-04-2024 Meike Kerstens resigns as director Director changes
  • Meike Kerstens, Bestuurder
Summary: v3.2
2023
22-12-2023 Change in the board of directors Director changes
Summary: v3.2
11-07-2023 Change in the board of directors Director changes
Summary: v3.2
16-06-2023 2 reappointed Director changes
  • EY Réviseurs d'Entreprises, Commissaris
  • Jean Antoine De Los Frailes, Bestuurder
Summary: v3.2
2022
19-05-2022 Transaction in capital or shares Capital & shares
Summary: v3.2
10-03-2022 Publication in the Belgian Official Gazette, Miscellaneous Miscellaneous·Renaud Decroix
Summary: proposalNotary: Renaud Decroix · Wavre
20-01-2022 Capital increase of €5,909,587.77 to €79,163,943.87 Capital & shares
  • €73.254.356,10 → €79.163.943,87
Summary: v3.2
2021
30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation Open-capture extraction
  • Publication: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
  • Filing: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
  • General meeting: 2021-03-17 · Algemene Vereniging van de Geneesmiddelenindustrie
  • Officer appointment: role: bestuurder, start_date: 2021-03-17 · Takeda Belgium N.V.
  • Officer reappointment: role: bestuurder, start_date: 2021-03-17 · AbbVie N.V.
  • Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Amgen N.V.
  • Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Eli Lilly Benelux N.V.
  • Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Pfizer N.V.
  • Officer resignation: role: bestuurder, end_date: 2021-03-17 · Merck N.V.
  • Permanent representative · Laurerit Henaux
  • Officer appointment: role: CEO, belast met het dagelijks bestuur · Caroline Ven
Summary: General meeting · Officer appointment · Officer reappointment · Officer resignation
30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation Open-capture extraction
  • Publication: 2021-01-01 · Association Générale de l'Industrie du Médicament
  • Filing: 2021-04-23 · Association Générale de l'Industrie du Médicament
  • General meeting: 2021-03-17 · Association Générale de l'Industrie du Médicament
  • Officer appointment: role: administrateur, start_date: 2021-03-17 · Takeda Belgium S.A.
  • Officer reappointment: role: administrateur, start_date: 2021-03-17 · AbbVie S.A.
  • Officer reappointment: role: administrateur, start_date: 2021-03-17 · Amgen S.A.
  • Officer reappointment: role: administrateur, start_date: 2021-03-17 · Eli Lilly Benelux S.A.
  • Officer reappointment: role: administrateur, start_date: 2021-03-17 · Pfizer S.A.
  • Officer resignation: date: 2021-03-17, role: administrateur · Merck S.A.
  • Permanent representative · Laurent Henaux
Summary: General meeting · Officer appointment · Officer reappointment · Officer resignation
2020
22-09-2020 2 directors appointed, 2 resigning Director changes
  • Renaud Decroix, Bestuurder
  • Renaud Decroix, Gedelegeerd bestuurder
  • Thibault Massart, Bestuurder
  • Thibault Massart, Gedelegeerd bestuurder
Summary: v3.2
11-08-2020 Articles of association amended Statutes amendment
Summary: v3.2
09-03-2020 Eric Van Hoof reappointed as statutory auditor Director changes
  • Eric Van Hoof, Commissaris
Summary: v3.2
2019
14-05-2019 1 director appointed, 1 resigning Director changes
  • Robert Andrew Michael, Bestuurder
  • William Chase, Bestuurder
Summary: v3.2
2018
09-07-2018 General meeting · Officer appointment · Officer reappointment · Officer resignation Open-capture extraction
  • Publication: 09/07/2018 · Association Générale de l'Industrie du Médicament
  • Filing: 20/06/2018 · Association Générale de l'Industrie du Médicament
  • General meeting: 23/03/2018 · Association Générale de l'Industrie du Médicament
  • Officer appointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Amgen S.A.
  • Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · AbbVie S.A.
  • Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Celgene S.P.R.L.
  • Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Eli Lilly Benelux S.A.
  • Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Pfizer S.A.
  • Officer resignation: date: 2018-03-23, role: Membre du Conseil d'administration · Boehringer Ingelheim SCS
  • Board meeting: 30/05/2018 · Association Générale de l'Industrie du Médicament
  • Officer appointment: role: Président du Conseil d'administration, term: deux ans, start_date: 2018-05-30 · Pfizer S.A.
  • Officer appointment: role: Vice-Président du Conseil d'administration, term: deux ans, start_date: 2018-05-30 · MSD Belgium
Summary: General meeting · Officer appointment · Officer reappointment · Officer resignation
First 20 of 28 acts

Analysis

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Same sector, nearest first

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Groothandel in farmaceutische producten46460Groothandel in farmaceutische en medische artikelen46460
Primary activity highlighted.
Names & trade names
Legal nameFR ABBVIE
Registered office
Avenue Einstein 14
1300 Wavre, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.